Should I buy or sell Icosavax stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Icosavax in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ICVX shares. View ICVX analyst ratings or view top-rated stocks .

What is Icosavax's stock price target for 2024?

3 brokers have issued 12-month price objectives for Icosavax's stock. Their ICVX share price targets range from $25.00 to $28.00. On average, they anticipate the company's share price to reach $26.50 in the next twelve months. This suggests a possible upside of 166.6% from the stock's current price. View analysts price targets for ICVX or view top-rated stocks among Wall Street analysts .

How have ICVX shares performed in 2023?

Icosavax's stock was trading at $7.94 at the beginning of the year. Since then, ICVX shares have increased by 25.2% and is now trading at $9.94. View the best growth stocks for 2023 here .

When is Icosavax's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 4th 2024. View our ICVX earnings forecast .

How were Icosavax's earnings last quarter?

Icosavax, Inc. (NASDAQ:ICVX) issued its quarterly earnings data on Monday, November, 15th. The company reported ($1.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.49) by $0.81. The company had revenue of $1.83 million for the quarter, compared to analyst estimates of $3.30 million.

What ETFs hold Icosavax's stock?

ETFs with the largest weight of Icosavax (NASDAQ:ICVX) stock in their portfolio include ETFMG Treatments Testing and Advancements ETF (GERM) and Fidelity Disruptive Medicine ETF (FMED) .

When did Icosavax IPO?

(ICVX) raised $150 million in an IPO on Thursday, July 29th 2021. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share.

Who are Icosavax's major shareholders?

Icosavax's stock is owned by a variety of institutional and retail investors. Top institutional investors include FMR LLC (10.90%), Citigroup Inc. (0.63%), Northern Trust Corp (0.54%), Barclays PLC (0.40%), Bank of New York Mellon Corp (0.18%) and GSA Capital Partners LLP (0.05%). Insiders that own company stock include Adam K Simpson, Cassia Cearley , Charles E Richardson, Douglas Holtzman, Elizabeth Bekiroglu, Mark Mcdade, Niranjan Kanesa-Thasan, Ra Capital Management, LP and Thomas Joseph Russo. View institutional ownership trends .

How do I buy shares of Icosavax?

Shares of ICVX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Icosavax Stock Price, News & Analysis (NASDAQ:ICVX)

$9.94

-0.29 (-2.83%)

(As of 02:34 PM ET)

Compare

Today's Range: $9.92
▼
$10.82
50-Day Range: $5.95
▼
$11.24
52-Week Range: $3.09
▼
$16.45

Volume: 575,292 shs
Average Volume: 230,907 shs
Market Capitalization: $497.89 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $26.50

Icosavax MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 166.6% Upside
$26.50 Price Target
Short Interest: Bearish
5.49% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.81
Based on 3 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($2.20) to ($2.21) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.95 out of 5 stars

Medical Sector

656th out of 949 stocks

Biological Products, Except Diagnostic Industry

109th out of 163 stocks

3.5

Analyst's Opinion

Consensus Rating
Icosavax has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $26.50, Icosavax has a forecasted upside of 166.6% from its current price of $9.94.
Amount of Analyst Coverage
Icosavax has only been the subject of 3 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
5.49% of the float of Icosavax has been sold short.
Short Interest Ratio / Days to Cover
Icosavax has a short interest ratio ("days to cover") of 6.6.
Change versus previous month
Short interest in Icosavax has recently increased by 2.89%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Icosavax does not currently pay a dividend.
Dividend Growth
Icosavax does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ICVX.

2.7

News and Social Media Coverage

News Sentiment
Icosavax has a news sentiment score of 0.81. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Icosavax this week, compared to 1 article on an average week.
Search Interest
7 people have searched for ICVX on MarketBeat in the last 30 days. This is an increase of 250% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Icosavax insiders have not sold or bought any company stock.
Percentage Held by Insiders
30.59% of the stock of Icosavax is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
92.59% of the stock of Icosavax is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Icosavax are expected to decrease in the coming year, from ($2.20) to ($2.21) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Icosavax is -4.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Icosavax is -4.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Icosavax has a P/B Ratio of 2.14. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Icosavax Stock (NASDAQ:ICVX)

Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases through virus-like particle (VLP) platform technology. Its lead product candidate IVX-A12, a respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) VLP vaccine. The company also develops IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical trial; and IVX-241, a vaccine candidate with hMPV target. Icosavax, Inc. was incorporated in 2017 and is headquartered in Seattle, Washington.

ICVX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ICVX Stock News Headlines

November 27, 2023 | msn.com

Icosavax (ICVX) Price Target Increased by 5.00% to 24.99

November 26, 2023 | americanbankingnews.com

Icosavax (NASDAQ:ICVX) Trading 6.1% Higher

November 30, 2023 | Tomorrow Investor (Ad)

Why Microsoft Just Placed A Huge Bet On Nuclear

Even with aggressive expansion and acquisition of solar and wind farms, renewable energy isn’t anywhere close to providing the energy that Microsoft demands.

November 18, 2023 | msn.com

Guggenheim Initiates Coverage of Icosavax (ICVX) with Buy Recommendation

November 17, 2023 | realmoney.thestreet.com

Icosavax initiated with a Buy at Guggenheim

November 16, 2023 | markets.businessinsider.com

TD Cowen Keeps Their Buy Rating on Icosavax (ICVX)

November 15, 2023 | markets.businessinsider.com

Target Reports Earnings Beat, Joins AST SpaceMobile, Dada Nexus And Other Big Stocks Moving Higher On Wednesday

November 15, 2023 | finanznachrichten.de

Icosavax, Inc.: Icosavax Reports Third Quarter 2023 Financial Results and Provides Corporate Update

November 30, 2023 | Edge On The Street (Ad)

Gold Could Be Heading for Record Highs - But How to Play It?

According to FX Empire, the gold forecast is now bullish, with support for a $3,000 target in 2024. The big question is how to play it. Some investors are discovering a unique gold investment alternative that sidesteps the major issues with gold mining stocks or physical gold.

November 14, 2023 | finance.yahoo.com

Icosavax Inc (ICVX) Reports Q3 2023 Financial Results and Corporate Progress

November 14, 2023 | finance.yahoo.com

Icosavax Reports Third Quarter 2023 Financial Results and Provides Corporate Update

November 10, 2023 | seekingalpha.com

Aura Biosciences GAAP EPS of -$0.48

November 8, 2023 | finance.yahoo.com

Icosavax to Participate in the Jefferies London Healthcare Conference

October 31, 2023 | finance.yahoo.com

Icosavax to Participate in the Guggenheim Healthcare Talks 5th Annual Inflammation, Neurology & Immunology (INI) Conference

October 30, 2023 | finance.yahoo.com

We're Not Very Worried About Icosavax's (NASDAQ:ICVX) Cash Burn Rate

September 19, 2023 | finance.yahoo.com

Icosavax to Participate in the Cantor Fitzgerald Global Healthcare Conference 2023

August 15, 2023 | markets.businessinsider.com

Jefferies Reaffirms Their Buy Rating on Icosavax (ICVX)

August 14, 2023 | finance.yahoo.com

Icosavax Reports Second Quarter 2023 Financial Results and Provides Corporate Update

August 8, 2023 | finance.yahoo.com

Icosavax Reports Positive 12-Month Durability Data for VLP Vaccine Candidate IVX-121 Against RSV and Initial Evidence for Revaccination Potential

July 2, 2023 | finance.yahoo.com

Icosavax, Inc. (NASDAQ:ICVX) is largely controlled by institutional shareholders who own 53% of the company

June 20, 2023 | finance.yahoo.com

Icosavax Initiates Phase 2 Trial of IVX-A12 Against RSV and hMPV in Older Adults

June 15, 2023 | benzinga.com

Icosavax EVP Awarded $1.79M Worth of Stock Options

May 24, 2023 | finance.yahoo.com

Icosavax (ICVX) Up on Positive VLP Vaccine Candidate Data

May 23, 2023 | finance.yahoo.com

Why Shares of Icosavax Jumped on Tuesday

May 23, 2023 | msn.com

CohBar, Ocean Biomedical top healthcare gainers; NantHealth, Microbot among losers

May 23, 2023 | markets.businessinsider.com

Icosavax Touts Encouraging Early-Cut Data From Phase 1 Trial Of RSV Vaccine

May 22, 2023 | benzinga.com

Icosavax Announces Positive Topline Interim Phase 1 Results for Bivalent VLP Vaccine Candidate IVX-A12 Against RSV and hMPV in Older Adults

See More Headlines

Receive ICVX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Icosavax and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/15/2021
Today: 11/30/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 4/04/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:ICVX
CUSIP: N/A
CIK: 1786255
Web: icosavax.com
Phone: 206-737-0085
Fax: N/A
Employees: 60
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $26.50
High Stock Price Target: $28.00
Low Stock Price Target: $25.00
Potential Upside/Downside: +159.0%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.22)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-91,760,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -43.06%
Return on Assets: -39.53%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 18.06
Quick Ratio: 18.06

Sales & Book Value

Annual Sales: $580,000.00
Price / Sales: 883.48
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $4.64 per share
Price / Book: 2.20

Miscellaneous

Outstanding Shares: 50,090,000
Free Float: 34,767,000
Market Cap: $512.42 million
Optionable: Not Optionable
Beta: 0.45

7 Energy Stocks to Buy and Hold Forever

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

Mr. Adam K. Simpson (Age 47)
President, CEO, Co-Founder & Director
Comp: $855.95k
Mr. Niranjan Kanesa-thasan M.D. (Age 62)
Chief Medical Officer
Comp: $641.55k
Dr. Cassia Cearley Ph.D. (Age 40)
Treasurer & Chief Business Officer
Comp: $632.15k
Mr. Neil King Ph.D.
Chair of Scientific Advisory Board & Co-Founder
Dr. David Baker M.D.
Ph.D., Co-founder & Member of Scientific Advisory Board
Mr. Thomas Joseph Russo C.F.A. (Age 51)
Chief Financial Officer
Comp: $525.27k
Ms. Jennifer Raymond
Senior Vice President of Technical Operations
Ms. Elizabeth Bekiroglu (Age 53)
General Counsel & Corporate Secretary
Comp: $230.74k
Ms. Lori Stewart
Senior Vice President of People & Culture
Dr. Ami Shah Brown MPH
Ph.D., Senior Vice President of Regulatory Affairs

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ICVX Stock Analysis - Frequently Asked Questions

Should I buy or sell Icosavax stock right now?: 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Icosavax in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ICVX shares.
View ICVX analyst ratings or view top-rated stocks.
What is Icosavax's stock price target for 2024?: 3 brokers have issued 12-month price objectives for Icosavax's stock. Their ICVX share price targets range from $25.00 to $28.00. On average, they anticipate the company's share price to reach $26.50 in the next twelve months. This suggests a possible upside of 166.6% from the stock's current price.
View analysts price targets for ICVX or view top-rated stocks among Wall Street analysts.
How have ICVX shares performed in 2023?: Icosavax's stock was trading at $7.94 at the beginning of the year. Since then, ICVX shares have increased by 25.2% and is now trading at $9.94.
View the best growth stocks for 2023 here.
When is Icosavax's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, April 4th 2024.
View our ICVX earnings forecast.
How were Icosavax's earnings last quarter?: Icosavax, Inc. (NASDAQ:ICVX) issued its quarterly earnings data on Monday, November, 15th. The company reported ($1.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.49) by $0.81. The company had revenue of $1.83 million for the quarter, compared to analyst estimates of $3.30 million.

What ETFs hold Icosavax's stock?: ETFs with the largest weight of Icosavax (NASDAQ:ICVX) stock in their portfolio include ETFMG Treatments Testing and Advancements ETF (GERM) and Fidelity Disruptive Medicine ETF (FMED).
When did Icosavax IPO?: (ICVX) raised $150 million in an IPO on Thursday, July 29th 2021. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share.
Who are Icosavax's major shareholders?: Icosavax's stock is owned by a variety of institutional and retail investors. Top institutional investors include FMR LLC (10.90%), Citigroup Inc. (0.63%), Northern Trust Corp (0.54%), Barclays PLC (0.40%), Bank of New York Mellon Corp (0.18%) and GSA Capital Partners LLP (0.05%). Insiders that own company stock include Adam K Simpson, Cassia Cearley, Charles E Richardson, Douglas Holtzman, Elizabeth Bekiroglu, Mark Mcdade, Niranjan Kanesa-Thasan, Ra Capital Management, LP and Thomas Joseph Russo.
View institutional ownership trends.
How do I buy shares of Icosavax?: Shares of ICVX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:ICVX) was last updated on 11/30/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial